Galderma Group AGXSWX:GALD +0.81%15 3-Year RORE % is 88.22 as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 936 Drug Manufacturers companies, Galderma Group AG ranks better than 89.74% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Galderma Group AG's 3-Year RORE % for the quarter that ended in Dec. 2025 was 88.22%.
The industry rank for Galderma Group AG's 3-Year RORE % or its related term are showing as below:
XSWX:GALD's 3-Year RORE % is ranked better than 89.74% of 936
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs XSWX:GALD: 88.22
Galderma Group AG (XSWX:GALD) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Galderma Group AG 3-Year RORE % Related Terms
Galderma Group AG 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Galderma Group AG (XSWX:GALD) has a 3-Year RORE % of 88.22 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #96 out of 936 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Galderma Group AG's 3-Year RORE % too high?
Galderma Group AG's current 3-Year RORE % is 88.22. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Galderma Group AG's value of 88.22 is 2768.9% above this industry median. Based on the distribution chart, Galderma Group AG ranks #96 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #96 out of 936 companies for 3-Year RORE %. This places Galderma Group AG in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. Galderma Group AG's value of 88.22 is 2768.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current 3-Year RORE % of 88.22 is 2768.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current 3-Year RORE % is 88.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current 3-Year RORE % of 88.22. The current 3-Year RORE % is 88.22 and 2768.9% above the Drug Manufacturers industry median of 3.08. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current 3-Year RORE % is 88.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 